Latest Healthcare It News

nib Holdings reported a solid FY25 with underlying operating profit of $239.2 million and 3.2% policyholder growth, driven by digital innovation and operational efficiencies. The Group’s strategic focus on core health insurance and adjacent services sets the stage for continued momentum into FY26.

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.

Ansell Limited reported record FY25 sales and EBIT margins, completing KBU integration ahead of schedule and upgrading synergy targets. The company guides higher adjusted EPS for FY26, fully offsetting US tariff hikes through pricing.

Ansell Limited reports robust FY25 growth driven by strong Industrial and Healthcare segments, completes KBU acquisition integration ahead of schedule, and announces a $200 million share buyback for FY26.

Ansell Limited has announced an unfranked ordinary dividend of USD 0.28 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan available to select shareholders.

Perpetual Credit Income Trust reported a 20.7% increase in net assets to $532.8 million for FY25, while posting a modest profit decline amid challenging market conditions. The Trust’s $93 million capital raise and diversified credit portfolio underpin its strategy for stable income and growth.

Universal Biosensors Inc. has been suspended from ASX trading following the appointment of voluntary administrators, highlighting serious financial distress within the company.

The ASX has suspended the securities of 36 companies for failing to pay their annual listing fees by the August 21 deadline, with a looming delisting threat if fees remain unpaid by August 28.

Zip Co has delivered a standout FY25 with cash earnings soaring 147%, driven by rapid US market expansion. The company is now considering a Nasdaq dual listing to fuel further growth.

Cogstate Limited reported a 22.3% rise in total revenue to US$53.1 million for FY25, driven by strong Clinical Trials growth, while profit before tax nearly doubled to US$13.9 million. The company also declared its inaugural fully franked dividend.

Sonic Healthcare has delivered solid FY 2025 results, meeting EBITDA guidance with 5% organic revenue growth and setting the stage for up to 19% EPS growth in FY 2026, driven by strategic acquisitions and operational synergies.

Sonic Healthcare delivered solid FY2025 results with 8% revenue growth and a 7% rise in net profit, setting the stage for an anticipated 19% earnings per share increase in FY2026.